US Patent

US12061183 — Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug

Formulation · Assigned to Abraxis Bioscience LLC · Expires 2036-03-05 · 10y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for assessing the suitability of a pharmaceutical composition containing nanoparticles of rapamycin coated with albumin and a non-nanoparticle portion of albumin and rapamycin.

USPTO Abstract

The present invention provides methods of assessing suitability of a pharmaceutical composition for medical use. The pharmaceutical composition comprises nanoparticles comprising rapamycin coated with albumin and a non-nanoparticle portion comprising albumin and rapamycin.

Drugs covered by this patent

Patent Metadata

Patent number
US12061183
Jurisdiction
US
Classification
Formulation
Expires
2036-03-05
Drug substance claim
No
Drug product claim
Yes
Assignee
Abraxis Bioscience LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.